Specifically, in the CheckMate067 trial, 22% of treatment-naïve metastatic melanoma patients achieved a CR upon combined checkpoint-inhibitor therapy with ipilimumab + nivolumab with slightly better survival outcomes for BRAF-mutant melanoma patients, which showed a median PFS of 16.8 months [8]. This evidence concerns the gene BRAF and metastatic melanoma.